Introduction
Growth hormone secretagogues (GHS) are a class of compounds — including both synthetic peptides and small molecules — that stimulate the release of growth hormone from the pituitary gland through mechanisms distinct from native GHRH. Understanding what growth hormone secretagogues are, how they work, and how they differ from each other is foundational for researchers working with GH axis peptides.
Discovery of the GHS Receptor
The story of growth hormone secretagogues begins with a somewhat unexpected discovery. In the 1970s and 1980s, researchers identified synthetic peptide and non-peptide compounds that could stimulate GH release through a mechanism that was distinct from GHRH and could not be blocked by GHRH antagonists. These compounds were called growth hormone secretagogues. Their receptor — the GHS receptor (GHS-R1a) — was identified and cloned in 1996. Shortly afterward, it was discovered that ghrelin — a natural gut-derived peptide — was the endogenous ligand for this receptor, establishing ghrelin as the natural GHS.
The Ghrelin Receptor (GHS-R1a)
GHS-R1a is a G protein-coupled receptor highly expressed in the pituitary gland, hypothalamus, and other brain regions. Activation of GHS-R1a by ghrelin or synthetic GHS compounds triggers GH release through signaling pathways that are complementary to — but distinct from — GHRH receptor signaling. GHS-R1a activation primarily increases GH pulse frequency, while GHRH receptor activation increases GH pulse amplitude. This is why combining a GHS with a GHRH analogue (such as Ipamorelin + CJC-1295) produces synergistic GH release.
GHS-R1a Beyond GH: Appetite and Metabolism
GHS-R1a is not only a GH regulator — it also mediates appetite stimulation, gastric motility, and glucose metabolism. Ghrelin’s well-known hunger-stimulating role is mediated through GHS-R1a. This is why GH-releasing peptides like GHRP-6 that strongly activate GHS-R1a also stimulate appetite in animal studies. More selective GHRPs like Ipamorelin cause less appetite stimulation, reflecting more selective receptor engagement.
Peptide GHS Compounds
The most commonly studied peptide GHS compounds include: GHRP-6 (the prototypic synthetic GHRP), GHRP-2 (more potent but also more cortisol-elevating), Ipamorelin (highly selective for GH with minimal cortisol or appetite effects), Hexarelin (most potent GHRP with additional CD36 cardiac activity), and native ghrelin and its various analogues.
Non-Peptide GHS
Several non-peptide oral GHS compounds have been developed for research and pharmaceutical applications, including MK-677 (Ibutamoren) — an orally active, long-acting GHS-R1a agonist that has been studied in clinical trials for GH deficiency and sarcopenia. While not a peptide, MK-677 is often discussed in the context of peptide GHS research as a comparator compound.
Clinical Research with GHS
GHS compounds have been evaluated in clinical trials for GH deficiency, frailty and sarcopenia in aging, HIV wasting, and as diagnostic tools for GH axis assessment. The most advanced clinical development has been with MK-677 (oral) and Ibutamoren. Hexarelin has been studied in human cardiac function research. Macimorelin — an oral GHS compound — received FDA approval as a diagnostic for adult GH deficiency.
Conclusion
Growth hormone secretagogues represent a pharmacologically diverse class of compounds unified by their action through the ghrelin receptor to stimulate GH release. Their differential selectivity profiles — ranging from GHRP-6’s broad ghrelin pathway activation to Ipamorelin’s clean GH-selective stimulation — provide research tools for studying GH axis pharmacology with different levels of receptor pathway specificity.